13/07/2026 Novartis received Health Canada approval for VANRAFIA™ to reduce proteinuria in adults with primary IgAN IQIRVO® demonstrated statistically significant improvement in ALP normalization in patients with PBC in Phase 3b study Q32 Bio announced results from Part B of the Phase 2a study of bempikibart in Alopecia Areata Novartis received Health Canada approval for VANRAFIA™ to reduce proteinuria in adults with primary IgAN (Ref) Novartis Pharmaceuticals Canada announce

02/06/2026 Gilead announced positive phase 3 results for Seladelpar in PBC Vera Therapeutics announced US FDA alignment on an earlier ORIGIN phase 3 eGFR analysis to support potential full approval for atacicept in adults with IgA Nephropathy Rise Therapeutics announced completion of enrollment in the 4-Week dose expansion cohort for R-2487 in RA clinical trial Gilead announced positive phase 3 results for Seladelpar in PBC (Ref) Gilead Sciences announced positive results fro

19/03/2026 GSK announced FDA approval of linerixibat for adult patients with PBC GSK announced FDA approval of linerixibat for adult patients with PBC ( Ref ) GSK announced that the US FDA had approved Lynavoy (linerixibat; an IBAT inhibitor) for the treatment of cholestatic pruritus in adult patients with primary biliary cholangitis (PBC) The approval was based on data from the global Phase 3, GLISTEN/ NCT04950127 trial The trial met both primary and key secondary endpoints,